<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Abaxis Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/abaxis-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 16 May 2012 17:53:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ABAX) Abaxis Analyst Upgrades Shares to Neutral</title>
		<link>http://www.stockbloghub.com/2011/12/01/abax-abaxis-analyst-upgrades-shares-to-neutral/87677</link>
		<comments>http://www.stockbloghub.com/2011/12/01/abax-abaxis-analyst-upgrades-shares-to-neutral/87677#comments</comments>
		<pubDate>Thu, 01 Dec 2011 15:16:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABAX]]></category>
		<category><![CDATA[Abaxis Inc.]]></category>
		<category><![CDATA[IDEXX Laboratories Inc.]]></category>
		<category><![CDATA[IDXX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87677</guid>
		<description><![CDATA[Following the company’s solid second quarter 2011 results, which were ahead of the Zacks Consensus Estimates, we have upgraded our recommendation on Abaxis (ABAX) to Neutral with a target price of $26.00. The company reported EPS of 15 cents in the quarter, surpassing the Zacks Consensus Estimate by 2 cents. On the other hand, net sales increased 13% year over year to $40 million and beat the Zacks Consensus Estimate of $38 million. The year-over-year growth was based on higher sales in both North America (up 8% to $31.9 million) and in the international market (up 39.9% to $8.0 million). The overall balanced revenue growth in both North America and in the international market was encouraging, especially amid a tough global macro-economic environment. Abaxis is executing well in its veterinary ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/01/abax-abaxis-analyst-upgrades-shares-to-neutral/87677/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABAX) Alere Takes Over Arriva Medical</title>
		<link>http://www.stockbloghub.com/2011/12/01/abax-alere-takes-over-arriva-medical/87806</link>
		<comments>http://www.stockbloghub.com/2011/12/01/abax-alere-takes-over-arriva-medical/87806#comments</comments>
		<pubDate>Thu, 01 Dec 2011 15:15:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABAX]]></category>
		<category><![CDATA[Abaxis Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87806</guid>
		<description><![CDATA[Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, recently revealed that it has taken over Arriva Medical, a prominent vendor of diabetes testing supplies for patients residing at home. Florida-based Arriva had sales of about $21.5 million for the half year ending October 31, 2011. The company delivers diabetes supplies right to the patient’s home. It completes claim forms and bills Medicare as well as the supplemental insurance company for the patient. Alere paid about $65 million in cash to acquire Arriva, besides 806,452 restricted shares of its common stock. The deal is subject to working capital and various closing adjustments. By acquiring Arriva, Waltham-based Alere acquires fresh abilities to handle near-patient treatment. Alere’s expertise and product development efforts center around women’s health, infectious ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/01/abax-alere-takes-over-arriva-medical/87806/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABAX) Alere Quarterly Earnings Beats Estimates</title>
		<link>http://www.stockbloghub.com/2011/05/04/abax-alere-quarterly-earnings-beats-estimates/73155</link>
		<comments>http://www.stockbloghub.com/2011/05/04/abax-alere-quarterly-earnings-beats-estimates/73155#comments</comments>
		<pubDate>Wed, 04 May 2011 17:04:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABAX]]></category>
		<category><![CDATA[Abaxis Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73155</guid>
		<description><![CDATA[Alere (ALR), a medical products company focused on integrating rapid diagnostics with health management, reported first-quarter fiscal 2011 adjusted earnings per share of 61 cents, beating the corresponding Zacks Consensus Estimate of 57 cents while trailing the year-ago earnings from continuing operations of 64 cents a share. Reported net income was about $8.1 million (or 9 cents per share) in the first quarter compared with $9 million (11 cents per share) in the prior-year period, down 10% year over year. Reported net income in the most recent quarter contains, among other items, a gain of $19.6 million emanating from the disposition of the nutritional segment. Revenues Net revenues were $582.5 million in the reported quarter, up 13% year over year, surpassing the Zacks Consensus Estimate of $562 million. On a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/04/abax-alere-quarterly-earnings-beats-estimates/73155/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABAX) Abaxis Analyst Maintains Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/04/01/abax-abaxis-analyst-maintains-neutral-rating/32639</link>
		<comments>http://www.stockbloghub.com/2010/04/01/abax-abaxis-analyst-maintains-neutral-rating/32639#comments</comments>
		<pubDate>Thu, 01 Apr 2010 21:48:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABAX]]></category>
		<category><![CDATA[Abaxis Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32639</guid>
		<description><![CDATA[We recently reiterated our ‘Neutral’ rating on Abaxis, Inc. (ABAX) with a target price of $28, based on a P/E of 34.1x our fiscal 2011 EPS estimate of 82 cents. Abaxis’ results for the third quarter fiscal 2010 were mixed. Earnings per share for the third quarter was 15 cents, below the Zacks Consensus Estimate of 17 cents. However, earnings was flat on a year-over-year basis. Total revenue in the third quarter increased 15% year over year to $31 million, fueled by higher instrument unit sales. Revenues from instrument sales and consumables increased 6% and 20% year over year, respectively, in the third quarter. Total medical and veterinary instrument sales increased 37% year over year to 1,212 units. In terms of customer group: Veterinary market sales increased 33% year over ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/01/abax-abaxis-analyst-maintains-neutral-rating/32639/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABAX) Abaxis Thurd Quarter 2010 Report Misses Estimates</title>
		<link>http://www.stockbloghub.com/2010/02/01/abax-abaxis-thurd-quarter-2010-report-misses-estimates/26569</link>
		<comments>http://www.stockbloghub.com/2010/02/01/abax-abaxis-thurd-quarter-2010-report-misses-estimates/26569#comments</comments>
		<pubDate>Mon, 01 Feb 2010 18:06:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABAX]]></category>
		<category><![CDATA[Abaxis Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26569</guid>
		<description><![CDATA[Abaxis, Inc. (ABAX) reported third quarter fiscal 2010 earnings per share of 15 cents, missing the Zacks Consensus Estimate of 17 cents. However, earnings in the year-ago quarter were 15 cents. Sales Total revenues in the third quarter increased 15% year over year to $31.0 million, fueled by higher instrument unit sales. Revenues from instrument sales and consumables increased 6% and 20% year over year, respectively, in the third quarter. Total medical and veterinary instrument sales increased 37% year over year to 1,212 units. In terms of customer group: Veterinary market sales increased 33% year over year to $23.9 million due to higher veterinary reagent disc sales. Medical market sales declined 28% year over year to $5.2 million primarily due to a decline in instrument sales to the U.S. government ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/01/abax-abaxis-thurd-quarter-2010-report-misses-estimates/26569/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABAX) Abaxis Receives FDA Approval</title>
		<link>http://www.stockbloghub.com/2010/01/23/abax-abaxis-receives-fda-approval/25762</link>
		<comments>http://www.stockbloghub.com/2010/01/23/abax-abaxis-receives-fda-approval/25762#comments</comments>
		<pubDate>Sat, 23 Jan 2010 21:14:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABAX]]></category>
		<category><![CDATA[Abaxis Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25762</guid>
		<description><![CDATA[Abaxis, Inc. (ABAX) recently received the U.S. Food and Drug Administration (FDA) approval to market its new C-Reactive Protein (CRP) assay in the United States. The new C-Reactive Protein assay is used by healthcare professionals in conjunction with Abaxis’ Piccolo Xpress point-of-care analyzer to conduct on-site chemistry analysis for conditions like infections, inflammatory diseases, tissue injury and few neoplastic processes. The on-site chemistry analysis takes only twelve minutes to complete the process. It has been seen so that CRP is generally used by Rheumatologists in the detection and treatment of Rheumatoid Arthritis. In addition, the CRP test can be used in the detection and treatment of other afflictions like Colon Cancer, Non Hodgkin&#8217;s Lymphoma, Atrial fibrillation, fever from bacterial infections, and Osteomyelitis. The new product is an addition to Abaxis’ ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/23/abax-abaxis-receives-fda-approval/25762/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABAX) Abaxis Launches New Bird Flu Test Product</title>
		<link>http://www.stockbloghub.com/2009/12/29/abax-abaxis-launches-new-bird-flu-test-product/23868</link>
		<comments>http://www.stockbloghub.com/2009/12/29/abax-abaxis-launches-new-bird-flu-test-product/23868#comments</comments>
		<pubDate>Wed, 30 Dec 2009 01:07:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABAX]]></category>
		<category><![CDATA[Abaxis Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23868</guid>
		<description><![CDATA[Abaxis, Inc. (ABAX) reported that it has launched its first product, a rapid Avian Influenza Antigen Test, in the production animal diagnostics market. Avian Influenza Antigen Test is a disposable and USDA-licensed test for Avian Influenza Type A nucleoprotein antigen in chickens, turkeys and ducks. Abaxis has worldwide rights to market this product globally. Avian Influenza Antigen Test is capable of providing results in fifteen minutes. It can be performed on-field or in a laboratory of any size. Abaxis has a strong research and development team that evaluates various opportunities to leverage its intellectual property and other joint product development ventures. Including Avian Influenza Antigen Test, the company has launched four new products in different fields to date in 2009. We think that the new product will boost Abaxis’ top-line. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/29/abax-abaxis-launches-new-bird-flu-test-product/23868/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABAX) Abaxis Earnings Report Lags Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2009/10/28/abax-abaxis-earnings-report-lags-consensus-estimates/19052</link>
		<comments>http://www.stockbloghub.com/2009/10/28/abax-abaxis-earnings-report-lags-consensus-estimates/19052#comments</comments>
		<pubDate>Wed, 28 Oct 2009 22:13:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABAX]]></category>
		<category><![CDATA[Abaxis Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19052</guid>
		<description><![CDATA[Abaxis Inc. (ABAX) reported second quarter fiscal 2010 earnings per share of 14 cents, lower than the Zacks Consensus Estimate of 17 cents and the year-ago earnings of 15 cents. Total revenues for the reported quarter were $30.3 million, logging a growth of 9% year over year. Growth was driven by strong medical and veterinary instrument and reagent disc sales. Medical and veterinary instrument sales grew 26% year over year to 926 units. Medical and veterinary reagent disc sales expanded 2% year over year to 1.5 million units. In terms of customer group: Medical market revenues increased 5% year over year to $6.3 million. Veterinary market revenues rose 9% year over year to roughly $21.7 million. In terms of products: Instrument sales declined 5% year-over-year due to lower average selling ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/28/abax-abaxis-earnings-report-lags-consensus-estimates/19052/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

